ThymidineCAS# 50-89-5 |
2D Structure
- Telbivudine
Catalog No.:BCC3862
CAS No.:3424-98-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 50-89-5 | SDF | Download SDF |
PubChem ID | 1134 | Appearance | Powder |
Formula | C10H14N2O5 | M.Wt | 242.2 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (206.42 mM; Need ultrasonic) H2O : 33.33 mg/mL (137.60 mM; Need ultrasonic) | ||
Chemical Name | 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione | ||
SMILES | CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O | ||
Standard InChIKey | IQFYYKKMVGJFEH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Thymidine is a pyrimidine nucleoside that is composed of the pyrimidine base thymine attached to the sugar deoxyribose. As a constituent of DNA, thymidine pairs with adenine in the DNA double helix. Thymidine could be a tracer in tumor cell examin. Thymidine overload due to Thymidine phosphorylase deficiency, and mitochondrial toxicity caused by antiviral Thymidine analogues. |
Targets | DNA/RNA Synthesis |
In vitro | In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy.[Pubmed: 8478710]J Nucl Med. 1993 May;34(5):773-9.
|
Kinase Assay | Thymidine kinase 2 enzyme kinetics elucidate the mechanism of thymidine-induced mitochondrial DNA depletion.[Pubmed: 25215937]Biochemistry. 2014 Oct 7;53(39):6142-50.Mitochondrial Thymidine kinase 2 (TK2) is a nuclear gene-encoded protein, synthesized in the cytosol and subsequently translocated into the mitochondrial matrix, where it catalyzes the phosphorylation of Thymidine (dT) and deoxycytidine (dC). The kinetics of Thymidine phosphorylation exhibits negative cooperativity, but dC phosphorylation follows hyperbolic Michaelis-Menten kinetics. The two substrates compete with each other in that Thymidine is a competitive inhibitor of dC phosphorylation, while dC acts as a noncompetitive inhibitor of Thymidine phosphorylation. In addition, TK2 is feedback inhibited by dTTP and dCTP. Thymidine kinase 2 also phosphorylates a number of pyrimidine nucleoside analogues used in antiviral and anticancer therapy and thus plays an important role in mitochondrial toxicities caused by nucleoside analogues. Deficiency in Thymidine kinase 2 activity due to genetic alterations causes devastating mitochondrial diseases, which are characterized by mitochondrial DNA (mtDNA) depletion or multiple deletions in the affected tissues. Severe Thymidine kinase 2 deficiency is associated with early-onset fatal mitochondrial DNA depletion syndrome, while less severe deficiencies result in late-onset phenotypes. |
Thymidine Dilution Calculator
Thymidine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.1288 mL | 20.6441 mL | 41.2882 mL | 82.5764 mL | 103.2205 mL |
5 mM | 0.8258 mL | 4.1288 mL | 8.2576 mL | 16.5153 mL | 20.6441 mL |
10 mM | 0.4129 mL | 2.0644 mL | 4.1288 mL | 8.2576 mL | 10.322 mL |
50 mM | 0.0826 mL | 0.4129 mL | 0.8258 mL | 1.6515 mL | 2.0644 mL |
100 mM | 0.0413 mL | 0.2064 mL | 0.4129 mL | 0.8258 mL | 1.0322 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ascorbic acid
Catalog No.:BCN2207
CAS No.:50-81-7
- Aspirin (Acetylsalicylic acid)
Catalog No.:BCC2097
CAS No.:50-78-2
- Actinomycin D
Catalog No.:BCC2385
CAS No.:50-76-0
- 1,3:2,4-Di-p-methylbenyliedene sorbitol
Catalog No.:BCC4847
CAS No.:54686-97-4
- 5-Hydroxytryptamine
Catalog No.:BCC9204
CAS No.:50-67-9
- Niclosamide
Catalog No.:BCC5081
CAS No.:50-65-7
- Chloroquine diphosphate
Catalog No.:BCC3915
CAS No.:50-63-5
- Oxytocin
Catalog No.:BCC5435
CAS No.:50-56-6
- Reserpine
Catalog No.:BCN4960
CAS No.:50-55-5
- Estradiol Benzoate
Catalog No.:BCC4779
CAS No.:50-50-0
- Mercaptopurine (6-MP)
Catalog No.:BCC1186
CAS No.:50-44-2
- Clomiphene citrate
Catalog No.:BCC4480
CAS No.:50-41-9
- Floxuridine
Catalog No.:BCC1187
CAS No.:50-91-9
- Ephedrine Hydrochloride
Catalog No.:BCC8322
CAS No.:50-98-6
- D-(+)-Glucose
Catalog No.:BCN1259
CAS No.:50-99-7
- Nordihydroguaiaretic acid
Catalog No.:BCC1805
CAS No.:500-38-9
- L-Mimosine
Catalog No.:BCC5450
CAS No.:500-44-7
- Apoatropine
Catalog No.:BCN1869
CAS No.:500-55-0
- Convolamine
Catalog No.:BCN1905
CAS No.:500-56-1
- Yangonin
Catalog No.:BCN3565
CAS No.:500-62-9
- Kawain
Catalog No.:BCN3564
CAS No.:500-64-1
- Rhapontigenin
Catalog No.:BCN3515
CAS No.:500-65-2
- Olivetol
Catalog No.:BCN4629
CAS No.:500-66-3
- 3,5-Dimethoxyphenol
Catalog No.:BCN7198
CAS No.:500-99-2
In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy.[Pubmed:8478710]
J Nucl Med. 1993 May;34(5):773-9.
The tumor cell uptake of three tracers that can be labeled with isotopes suitable for PET imaging--FDG, L-methionine and Thymidine--were examined in vitro in a human ovarian carcinoma cell line (HTB77IP3) at varying times following 30 Gy 60Co irradiation and were compared to a nonirradiated control group. FDG, methionine and Thymidine uptake per tissue culture well all increased following irradiation when compared to basal values, although to a much lower extent than the increases in uptake seen in a nonirradiated group. This increase in tracer uptake occurred despite a 6.25-fold decline in viable cell numbers. When examined per cell, FDG uptake per cell increased 9.77-fold, methionine 7.82-fold and Thymidine 9.48-fold over basal levels from Day 0 to Day 12 following irradiation. Part of these increases may be due to giant cell formation and/or radiation repair processes that require energy, protein and DNA substrates. While the in vitro system differs from in vivo systems due to the absence of a blood supply in vitro, a lack of infiltrating leukocytes and other factors, our data suggest that early assessment of human adenocarcinoma response to radiotherapy by PET with these tracers may be complicated by this normal increase in tracer uptake postirradiation. Clearly, in this human cancer cell line, early radiation-induced cell death is not associated with an early decline in tumor cell uptake of FDG, methionine or Thymidine.
Thymidine kinase 2 enzyme kinetics elucidate the mechanism of thymidine-induced mitochondrial DNA depletion.[Pubmed:25215937]
Biochemistry. 2014 Oct 7;53(39):6142-50.
Mitochondrial Thymidine kinase 2 (TK2) is a nuclear gene-encoded protein, synthesized in the cytosol and subsequently translocated into the mitochondrial matrix, where it catalyzes the phosphorylation of Thymidine (dT) and deoxycytidine (dC). The kinetics of dT phosphorylation exhibits negative cooperativity, but dC phosphorylation follows hyperbolic Michaelis-Menten kinetics. The two substrates compete with each other in that dT is a competitive inhibitor of dC phosphorylation, while dC acts as a noncompetitive inhibitor of dT phosphorylation. In addition, TK2 is feedback inhibited by dTTP and dCTP. TK2 also phosphorylates a number of pyrimidine nucleoside analogues used in antiviral and anticancer therapy and thus plays an important role in mitochondrial toxicities caused by nucleoside analogues. Deficiency in TK2 activity due to genetic alterations causes devastating mitochondrial diseases, which are characterized by mitochondrial DNA (mtDNA) depletion or multiple deletions in the affected tissues. Severe TK2 deficiency is associated with early-onset fatal mitochondrial DNA depletion syndrome, while less severe deficiencies result in late-onset phenotypes. In this review, studies of the enzyme kinetic behavior of TK2 enzyme variants are used to explain the mechanism of mtDNA depletion caused by TK2 mutations, Thymidine overload due to Thymidine phosphorylase deficiency, and mitochondrial toxicity caused by antiviral Thymidine analogues.